NextCure Past Earnings Performance
Past criteria checks 0/6
NextCure's earnings have been declining at an average annual rate of -23.5%, while the Biotechs industry saw earnings growing at 12.7% annually. Revenues have been declining at an average rate of 43.8% per year.
Key information
-23.5%
Earnings growth rate
39.1%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | -43.8% |
| Return on equity | -54.8% |
| Net Margin | n/a |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
We're Keeping An Eye On NextCure's (NASDAQ:NXTC) Cash Burn Rate
Mar 23
We're Keeping An Eye On NextCure's (NASDAQ:NXTC) Cash Burn Rate
Dec 09Will NextCure (NASDAQ:NXTC) Spend Its Cash Wisely?
Aug 23Is NextCure (NASDAQ:NXTC) In A Good Position To Deliver On Growth Plans?
May 10We're Keeping An Eye On NextCure's (NASDAQ:NXTC) Cash Burn Rate
Nov 22Estimating The Intrinsic Value Of NextCure, Inc. (NASDAQ:NXTC)
Aug 09NextCure GAAP EPS of -$0.59
Aug 04We're Not Very Worried About NextCure's (NASDAQ:NXTC) Cash Burn Rate
May 02NextCure: Large Upside With Downside Protected By Cash Pile
Sep 29NextCure (NXTC) Presents at 7th Annual Truist Securities Life Sciences Summit - Slideshow
May 10NextCure EPS misses by $0.01
May 06Here's What NextCure, Inc.'s (NASDAQ:NXTC) Shareholder Ownership Structure Looks Like
Feb 12NextCure's (NASDAQ:NXTC) Shareholders Are Down 80% On Their Shares
Jan 08NextCure provides update on NC318 clinical program
Dec 17Revenue & Expenses BreakdownBeta
How NextCure makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 0 | -63 | 20 | 48 |
| 30 Sep 23 | 0 | -66 | 21 | 54 |
| 30 Jun 23 | 0 | -70 | 22 | 51 |
| 31 Mar 23 | 0 | -70 | 21 | 51 |
| 31 Dec 22 | 0 | -75 | 22 | 54 |
| 30 Sep 22 | 0 | -74 | 22 | 50 |
| 30 Jun 22 | 0 | -73 | 21 | 78 |
| 31 Mar 22 | 0 | -73 | 21 | 53 |
| 31 Dec 21 | 0 | -69 | 21 | 50 |
| 30 Sep 21 | 0 | -68 | 20 | 0 |
| 30 Jun 21 | 0 | -66 | 20 | 0 |
| 31 Mar 21 | 0 | -63 | 18 | 12 |
| 31 Dec 20 | 22 | -37 | 17 | 0 |
| 30 Sep 20 | 24 | -32 | 16 | 0 |
| 30 Jun 20 | 26 | -24 | 13 | 0 |
| 31 Mar 20 | 27 | -18 | 12 | 0 |
| 31 Dec 19 | 6 | -34 | 10 | 0 |
| 30 Sep 19 | 4 | -30 | 8 | 0 |
| 30 Jun 19 | 3 | -27 | 6 | 0 |
| 31 Mar 19 | 1 | -24 | 4 | 0 |
| 31 Dec 18 | 0 | -23 | 3 | 0 |
Quality Earnings: NXTC is currently unprofitable.
Growing Profit Margin: NXTC is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: NXTC is unprofitable, and losses have increased over the past 5 years at a rate of 23.5% per year.
Accelerating Growth: Unable to compare NXTC's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: NXTC is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-8.9%).
Return on Equity
High ROE: NXTC has a negative Return on Equity (-54.82%), as it is currently unprofitable.